Memantina Stada

Memantine hydrochloride, the active ingredient in Memantina Stada, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults and may help improve cognition, memory, and daily functioning.

GNH USA supplies Memantina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and regulatory requirements across EU and global markets.

Memantina Stada is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

- Alzheimer’s disease (moderate to severe): helps maintain cognitive abilities and daily activities in affected patients.

Memantina Stada may cause a range of adverse reactions. Most are mild and reversible, but some can be serious and require medical attention.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient difficulty concentrating or thinking clearly.

Serious or Rare Side Effects: - Seizures: uncontrolled electrical activity in the brain. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm that may require monitoring.

Before prescribing Memantina Stada, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of seizures: evaluate risk of seizure exacerbation. - Cardiovascular disease: monitor blood pressure and heart rate. - Concomitant NMDA antagonists: avoid combined use due to additive effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS effects and risk of severe dizziness. - Dextromethorphan: heightened risk of confusion and hallucinations.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensives: possible additive blood‑pressure lowering. - Anticholinergic agents: may worsen cognitive side effects. - Other anti‑dementia drugs (e.g., donepezil): monitor for combined adverse effects.